A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer

Trial Profile

A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs ISIS EIF4ERx (Primary) ; Irinotecan
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 22 Apr 2016 The treatment table has been amended to include one more arm. The dosing cycle of the drug has also been amended.
    • 22 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 20 Jun 2014 Planned End Date changed from 1 Jul 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top